[go: up one dir, main page]

CY1112620T1 - Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων - Google Patents

Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων

Info

Publication number
CY1112620T1
CY1112620T1 CY20111101006T CY111101006T CY1112620T1 CY 1112620 T1 CY1112620 T1 CY 1112620T1 CY 20111101006 T CY20111101006 T CY 20111101006T CY 111101006 T CY111101006 T CY 111101006T CY 1112620 T1 CY1112620 T1 CY 1112620T1
Authority
CY
Cyprus
Prior art keywords
basic protein
compositions
medical uses
mbp
myeline
Prior art date
Application number
CY20111101006T
Other languages
English (en)
Inventor
David Wraith
Heather Streeter
Original Assignee
Apitope Technology (Bristol) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721430A external-priority patent/GB0721430D0/en
Priority claimed from GB0800962A external-priority patent/GB0800962D0/en
Application filed by Apitope Technology (Bristol) Limited filed Critical Apitope Technology (Bristol) Limited
Publication of CY1112620T1 publication Critical patent/CY1112620T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με μια σύνθεση η οποία περιλαμβάνει τα ακόλουθα πεπτίδια βασικής πρωτεΐνης της μυελίνης: ΜΒΡ 30-44• ΜΒΡ 131-145• και ΜΒΡ 140-154. Η σύνθεση μπορεί να χρησιμοποιηθεί για αντιμετώπιση μιας νόσου, συγκεκριμένα σκλήρυνσης κατά πλάκας και/ή οπτικής νευρίτιδας και η εφεύρεση επίσης σχετίζεται με τέτοιες χρήσεις και μεθόδους.
CY20111101006T 2007-10-31 2011-10-25 Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων CY1112620T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0721430A GB0721430D0 (en) 2007-10-31 2007-10-31 Composition
GB0800962A GB0800962D0 (en) 2008-01-18 2008-01-18 Conposition
EP08844568A EP2211892B1 (en) 2007-10-31 2008-10-30 Compositions comprising myelin basic protein peptides and medical uses thereof

Publications (1)

Publication Number Publication Date
CY1112620T1 true CY1112620T1 (el) 2016-02-10

Family

ID=40591554

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101006T CY1112620T1 (el) 2007-10-31 2011-10-25 Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων

Country Status (24)

Country Link
US (3) US8623827B2 (el)
EP (1) EP2211892B1 (el)
JP (1) JP5361895B2 (el)
KR (1) KR101570383B1 (el)
CN (1) CN101848725B (el)
AT (1) ATE518546T1 (el)
AU (1) AU2008320657B2 (el)
BR (1) BRPI0818302B1 (el)
CA (1) CA2703170C (el)
CY (1) CY1112620T1 (el)
DK (1) DK2211892T3 (el)
EA (1) EA017999B1 (el)
EC (1) ECSP10010211A (el)
HK (1) HK1142803A1 (el)
HR (1) HRP20110724T1 (el)
IL (1) IL204662A (el)
MX (1) MX2010004698A (el)
MY (1) MY158800A (el)
NZ (1) NZ583924A (el)
PL (1) PL2211892T3 (el)
PT (1) PT2211892E (el)
SI (1) SI2211892T1 (el)
WO (1) WO2009056833A2 (el)
ZA (1) ZA201001748B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5431628B2 (ja) * 2000-08-21 2014-03-05 アピトープ テクノロジー （ブリストル） リミテッド ペプチド調査方法
BRPI0818302B1 (pt) 2007-10-31 2022-04-12 Apitope Technology (Bristol) Limited Composição
CA2780961C (en) * 2009-10-12 2018-10-02 Lifebio Laboratories Llc Composition for treatment of multiple sclerosis
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201603582D0 (en) * 2016-03-01 2016-04-13 Apitope Int Nv Peptides
US20200046802A1 (en) * 2017-01-04 2020-02-13 Apitope International Nv Therapeutic method using tolerogenic peptides
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
CA3072867A1 (en) * 2017-08-14 2019-02-21 Apitope Technology (Bristol) Limited Method
EP4323768A1 (en) 2021-04-16 2024-02-21 Cour Pharmaceuticals Development Company Inc. Method of tracking maintenance of immunological tolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
JP5431628B2 (ja) * 2000-08-21 2014-03-05 アピトープ テクノロジー （ブリストル） リミテッド ペプチド調査方法
US20040096456A1 (en) 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
BRPI0818302B1 (pt) 2007-10-31 2022-04-12 Apitope Technology (Bristol) Limited Composição

Also Published As

Publication number Publication date
IL204662A0 (en) 2010-11-30
EA017999B1 (ru) 2013-04-30
WO2009056833A3 (en) 2009-11-26
DK2211892T3 (da) 2011-10-31
BRPI0818302B1 (pt) 2022-04-12
US20160263188A1 (en) 2016-09-15
HRP20110724T1 (hr) 2011-12-31
IL204662A (en) 2013-07-31
CN101848725B (zh) 2013-05-22
CN101848725A (zh) 2010-09-29
EP2211892B1 (en) 2011-08-03
NZ583924A (en) 2012-06-29
US9775880B2 (en) 2017-10-03
MX2010004698A (es) 2010-05-13
EP2211892A2 (en) 2010-08-04
US20100286054A1 (en) 2010-11-11
BRPI0818302A2 (el) 2018-08-21
MY158800A (en) 2016-11-15
AU2008320657B2 (en) 2013-09-05
CA2703170C (en) 2016-10-11
WO2009056833A2 (en) 2009-05-07
US9381234B2 (en) 2016-07-05
EA201070541A1 (ru) 2010-12-30
US20140161832A1 (en) 2014-06-12
CA2703170A1 (en) 2009-05-07
AU2008320657A1 (en) 2009-05-07
SI2211892T1 (sl) 2011-12-30
JP2011500776A (ja) 2011-01-06
HK1142803A1 (en) 2010-12-17
KR101570383B1 (ko) 2015-11-19
PL2211892T3 (pl) 2012-01-31
ZA201001748B (en) 2011-06-29
US8623827B2 (en) 2014-01-07
ATE518546T1 (de) 2011-08-15
KR20100036391A (ko) 2010-04-07
PT2211892E (pt) 2011-10-18
ECSP10010211A (es) 2010-08-31
JP5361895B2 (ja) 2013-12-04

Similar Documents

Publication Publication Date Title
CY1112620T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πεπτιδια βασικης πρωτεϊνης της μυελινης και ιατρικες χρησεις αυτων
NL301089I2 (nl) imlifidase
CY1121971T1 (el) Παγιδες gdf για χρηση στη θεραπευτικη αντιμετωπιση της αναιμιας
EA201001322A1 (ru) Вакцины против хламидиоза
CY1118691T1 (el) Συνθεσεις και μεθοδοι χρησης για αντισωματα κατα σκληροστινης
ECSP13012609A (es) Composición farmacéutica
ECSP099833A (es) Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
EA201001883A1 (ru) Мутанты fgf21 и их применение
CY1116169T1 (el) Συνθεσεις και μεθοδοι χρησης πεπτιδιων προνησιδιων και αναλογων εξ' αυτων
EA201592264A1 (ru) Композиции, которые индуцируют хелперное действие т-клеток
CY1118665T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
EA201171220A1 (ru) Мутанты fgf21 и их применение
NO20082473L (no) Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander
MX2011010353A (es) Composicion farmaceutica.
CR11580A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
CY1112791T1 (el) Φαρμακευτικη χημικη συνθεση ζονισαμιδης παρατεταμενης αποδεσμευσης
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
MX385354B (es) Sales de xantilio 3,6-disustituidas.
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
NO20076405L (no) Anvendelse av 24-nor-UDCA
CY1117251T1 (el) Μεθοδοι θεραπευτικης αντιμετωπισης της σκληροδερμιας
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
MX2022000393A (es) Metodo.